Compare · AZN vs ESPR
AZN vs ESPR
Side-by-side comparison of AstraZeneca PLC (AZN) and Esperion Therapeutics Inc. (ESPR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and ESPR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $255.09B, about 311.3x ESPR ($819.5M).
- Over the past year, AZN is down 12.6% and ESPR is up 182.3% - ESPR leads by 194.9 points.
- ESPR has been more active in the news (39 items in the past 4 weeks vs 15 for AZN).
- Both have 25 recent analyst ratings on file.
- Company
- AstraZeneca PLC
- Esperion Therapeutics Inc.
- Price
- $164.47-3.04%
- $3.19+0.16%
- Market cap
- $255.09B
- $819.5M
- 1M return
- -9.74%
- +1.59%
- 1Y return
- -12.65%
- +182.30%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2013
- News (4w)
- 15
- 39
- Recent ratings
- 25
- 25
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Esperion Therapeutics Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest ESPR
- Amendment: SEC Form SCHEDULE 13G/A filed by Esperion Therapeutics Inc.
- Director Hoffman Robert E. returned 85,153 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover withholding tax
- Director Carroll J Martin returned 177,523 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover withholding tax
- Director Shepard Jay returned 164,472 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy tax liability
- Director Fischer Seth H. Z. returned 141,023 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)
- Director Thompson John Craig returned 79,873 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)
- Chief Commercial Officer Harlow John B. Jr. returned 424,536 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Chief Legal Officer Looker Benjamin returned 667,524 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
- Chief Financial Officer Halladay Benjamin returned 705,410 shares to the company, closing all direct ownership in the company (SEC Form 4) (for tax liability)
- President and CEO Koenig Sheldon L. returned 2,121,094 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)